


Alternatives to ATF as a cell retention device


Levitronix® Bioprocessing Conference 2026 Boston

Loïc Chappuis
18.06.2026



MERCK



Perfusion platform



Merck perfusion platform

Perfusion process

- Maintain all process parameters constant
- Maintain cell growth and cell renewal
- Keep the biomass constant







CRD = Cell Retention Device

Merck perfusion platform

Biomass and Viable Cell Volume

Biomass = Viable Cell Volume


Biomass gives a better indicator than Viable Cell Density (VCD), due to cell diameter shift.



Caso, Stefania & Aeby, Mathieu & Jordan, Martin & Guillot, Raphael & Bielser, Jean-Marc. (2022). Effects of pyruvate on primary metabolism and product quality for a high-density perfusion process. *Biotechnology and Bioengineering*. 119. 10.1002/bit.28033.

Merck perfusion platform

Overview of Current Filtration Process



Merck perfusion platform

ATF filters scalability



XCell ATF 1 Single-use Device



XCell ATF 2 Single-use Device



XCell ATF 6 Single-use Device



XCell ATF 10 Single-use Device

12

75

1440

6720


#Fibers

Basic principle: Increase the number of 60 cm fibers through the scales

→ All parameters will stay close through the scales: Shear rate, residence time, exchange rate, ATF to filtration ratio.

Merck perfusion platform

ATF filters scalability




Basic principle: Increase the number of 60 cm fibers through the scales.

→ All parameters will stay close through the scales: Shear rate, residence time, exchange rate, ATF to filtration ratio.

Merck perfusion platform

Technical limitations

3 x ATF10 in degraded mode




- To achieve perf rate of process, we are operating in degraded mode – with 'Y' pieces with increased pressure head.
 - 2 ATF10 correctly connected
 - 4 ATF10 in degraded mode
- Y pieces are not recommended by Repligen.
- No reconnection possible to the same port.

Info: last 2 kL run had a 10 days of control state before clogging (3000 L/day of harvest).

Limitations of ATF technology at large scale – sieving issues

Sieving at 2000 L scale using ATF



$$\text{Sieving} = 100 - \text{product retention} = \frac{\text{Harvest titer}}{\text{Bioreactor titer}} \times 100$$

WHY An alternative cell retention device



Operational failure
30% of ATF fail integrity in Pilot
1-2 deviations on ATF operations per GMP run (aborted)



Platform Limitation
16 days steady state, 2000 L bioreactor at 2 Working Volume/Day is very challenging to manage with ATF nowadays



Loss of trust in the alternative tangential flow technology

ATF is a monopoly




Cost of cell retention device is ~20% of a USP run of 2000 L 16 days at steady state

Hollowfiber filters design

Filter overview








Filter composition

Housing

PES fibers








Filtration principle

1 mm lumen ID

0.22 μm pore

Permeate

Retentate




Starling effect

Starling effect

retentate pressure < permeate pressure
Cleaning of the filter

Equilibrium
permeate pressure = retentate pressure

retentate pressure > permeate pressure
Fouling of the filter




Starling effect

- Can generate a cleaning of the filter
- Generate fouling of the filter
- Only the first half of the filter is used for filtration in a TFF

Harvest flow is considered negligible (~50x smaller)

Romann et al. (2023). Co-current filtrate flow in TFF perfusion processes: Decoupling transmembrane pressure from crossflow to improve product sieving. Biotechnology and Bioengineering, 121. doi:10.1002/bit.28589





Alternating Tangential Flow Filtration (ATF)



Harvest
(cell free)

ATF

(Alternating Tangential Flow Filtration)










High performance TFF (HPTFF)

Harvest
(cell free)

HPTFF
(High Performance
Tangential Flow
Filtration)






HPTFF

3.5 L crossflow comparison

Aim: create equivalent conditions for the 2 membranes.




- 3.8 LMH applied per filter
- 10% biomass


HPTFF

3.5 L crossflow comparison

Aim: create equivalent conditions for the 2 membranes.



- 3.8 LMH applied per filter
- 10% biomass



In this case: Higher flow improves performance, but too high flows might damage cells due to shear (filter or/and pump); an optimum is needed.

HPTFF

20 L perfusion wave bag



HPTFF

20 L perfusion wave bag



Filter:

- 3.8 LMH
- 7.14 mL/min/fiber



Culture:

- 10 L working volume
- 1.3 vvd
- 8.3% biomass or VCV

HPTFF

10 L perfusion wave bag

Test the best HPTFF retentate flow that was identified at a larger scale : **7.14 mL/min/fiber**



- HPTFF demonstrated good scalability in term of performances
- Pump scaling gets easier when going to higher scale

HPTFF

Conclusion

- HPTFF demonstrate a good scalability
- HPTFF is able to achieve good performances in specific conditions



However:




- The system is complex (needed accurate pressure sensors)
- The system is less flexible than rTFF
- One directional flow might lead to filter inlet clogging
- Scale down model (3.5 L) is complicated to achieve due to fluidics constraints



Cell aggregates at filter inlet


Reverse TFF (rTFF)





rTFF

20 L test in wave-bag



Filter:

- 3.74 LMH
- 6.70 mL/min/fiber


Culture:

- 15.1 L Working Volume
- 0.89 vvd
- 6.85% biomass or VCV



rTFF

Test 50 L in wave-bag




Filter:

- 3.79 LMH
- 1000 s^{-1}


Culture:

- 25 L Working Volume
- 2 vvd
- 20% biomass or VCV



rTFF

Early material generation in 50 L wave bag



Filter set-up developed with Levitronix and wave bag adaptation with larger tubing and deep tubes for better compatibility with rTFF.

rTFF

Early material generation in 50 L wave bag



Filter set-up developed with Levitronix and wave bag adaptation with larger tubing and deep tubes for better compatibility with rTFF.

Filter:


- 4.1 LMH
- 7.14 mL/min/fiber

Culture:

- 25 L Working Volume
- 2 vvd
- 50% biomass or VCV

rTFF

Early material generation in 50 L wave bag




Filter:

- 4.1 LMH
- 7.14 mL/min/fiber




Culture:

- 25 L Working Volume
- 2 vvd
- 50% biomass or VCV



Filter set-up developed with Levitronix and wave bag adaptation with larger tubing and deep tubes for better compatibility with rTFF.



200 L rTFF Pilot-Scale Skid Prototype



200 L rTFF Prototype with backup option





200 L rTFF Prototype running




200 L rTFF

Similar growth and metabolism between ATF and rTFF




200 L rTFF

No impact on product quality



LMW: Low Molecular Weight

HMW: High Molecular Weight




—N77 High mannose

—N109 High mannose

—N208 High mannose

200 L rTFF

Similar sieving profile between ATF and rTFF



Conclusion

rTFF as a cell retention device



Good performance at 20 and 50 L scale



Sieving is equivalent or better



40% cost decrease estimated for cell retention



Easier and more flexible set-up

Conclusion

rTFF as a cell retention device



Good performance at 20 and 50 L scale



Sieving is equivalent or better



40% cost decrease estimated for cell retention



Easier and more flexible set-up

Next Steps



Improve set-up and assembly at 200 L



Test different membranes at 3.5 L



Continue testing on 200 L pilot scale

Conclusion

Open questions

- How to implement rTFF in GMP production?
- How to make a smart design at 2 kL?
- What are the risks and challenges associated with this technology?
- How to wet efficiently the filters?
- Should we adapt conditions (LMH, crossflow, etc) for each process?
- Could we build model to predict performances of filters swap?
- Could we clean filters to optimized duration?

Thanks !

Any questions



Loïc Chappuis
Process expert
Merck KGaA
loic.chappuis@merckgroup.com